Uma Madhav Borate MD

Hematologic Oncology

Assistant Professor, Medicine, University of Alabama School of Medicine

460 W 10th Ave# L586Columbus, OH 43210
Phone+1 614-293-9869

Dr. Borate is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Borate's full profile Already have an account?

Education & Training

University of Alabama Hospital (Birmingham)Fellowship, Hematology and Medical Oncology, 2008 - 2011
Jefferson Health Medical Education/Jefferson Einstein Philadelphia HospitalResidency, Internal Medicine, 2004 - 2008
B.J. Medical College - University of PuneClass of 2003

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

OH State Medical License 2020 - 2028
OR State Medical License 2016 - 2023
AL State Medical License 2008 - 2016
PA State Medical License 2004 - 2008
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification Cerner Patient Portal and Powerchart, Cerner Corporation, 2013-2014, 2016-2017
CMS Meaningful Use Stage 2 Certification Cerner Patient Portal and Powerchart, Cerner Corporation, 2013-2014, 2016-2017
CMS Meaningful Use Stage 1 Certification MyHealth@UABMedicine, UAB Health System, 2013-2014, 2016-2017

Clinical Trials

Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia Start of enrollment: 2009 Apr 20
ACTIVE_NOT_RECRUITING
PHASE3
A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation Start of enrollment: 2013 Aug 12
COMPLETED
PHASE2
A Safety Study of SGN-CD19A for Leukemia and Lymphoma
COMPLETED
PHASE1

Publications & Presentations

PubMed

Tamibarotene with venetoclax and azacitidine in RARAacute myeloid leukemia: results from the SY-1425-202 study.
Thomas Cluzeau, Uma Borate, Christine McMahon, Pierre Fenaux, Mael Heiblig
Blood Neoplasia. 2026-11-01
CPX-351 in combination with ruxolitinib for advanced-phase myeloproliferative neoplasms: results of a phase 1 study.
Shivani Handa, Yazan Madanat, Kelly Pugh, Kaitlyn Dvorak-Kornaus, Qiuhong Zhao
Blood Neoplasia. 2026-11-01
Randomized phase II trial of liposomal cytarabine and daunorubicin with or without pomalidomide in newly diagnosed acute myeloid leukemia myelodysplasia-related.
Daniel T Peters, Kristin Koenig, Anastasia Ivanova, Jiajun He, Gail J Roboz
Haematologica. 2026-09-24

Journal Articles

Functional Genomic Landscape of Acute Myeloid Leukaemia
Christopher R Cogle, Patricia Kropf, Daniel A Pollyea, Uma Borate, Michael W Deininger, Nature

Abstracts/Posters

A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodyspl...
Uma Borate, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Dose Escalation Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Uma Borate, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Framework to Identify and Prioritize Candidate Inherited Myeloid Malignancy Germline Variants Leveraging the BEAT AML Cohort
Uma Borate, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

Newly Diagnosed AML Patient Samples Demonstrate High Degree of Concordance in Identification of Pathogenic Mutations By Next Generation Sequencing (NGS) Performed at E...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
RGL4 over Expression Correlates with Variation in Midostaurin Response in FLT3-ITD Mutant AML Samples
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
A Precision Medicine Heirarchical Classification Developed Using Variant Allele Frequency (VAF) for Treatment of Older Patients (Pts) with Acute Myeloid Leukemia (AML)...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Inside ASH25 with Talha BadarDecember 9th, 2025
Identification of Targeted Therapies for Rare Adult Mature T-cell Leukemia Using Functional Ex Vivo Screening of Primary Patient SamplesFebruary 9th, 2017
Social Factors Affect Leukemia SurvivalSeptember 14th, 2015